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Summary
The pancreas is a relative newcomer to the
stable of tissues with an intrinsic angiotensin-
generating system. The involvement of this
system in pancreatic activity will be
dependent on the angiotensin-generating
paths present in the pancreas and their precise
cellular location. Thus far, renin, angiotensin-
converting enzyme (ACE), angiotensin II and
AT1 and AT2 receptors have been found.
These are components of the “classical”
renin-angiotensin system. But there is
uncertainty as to their location and site of
action. Furthermore, it is not known which, if
any, alternative enzymes to renin and ACE
are present, which angiotensins in addition to
angiotensin II are generated and whether or
not there are receptors to angiotensin IV and
angiotensin-(1-7). Future research should
focus on these aspects in order to provide a
mechanistic basis to pancreatic physiological
functions and to pathological conditions of
clinical relevance.
Introduction
The enzymatic pathway, which leads to the
generation of the potent vasoconstrictor
octapeptide angiotensin II, is usually
understood in terms of the “renin-angiotensin
system” (RAS) [1, 2, 3], where the hepatic
glycoprotein angiotensinogen is hydrolyzed
by the renal enzyme renin in the circulating
blood. The decapeptide product, angiotensin I
is subsequently converted to angiotensin II by
the pulmonary membrane-bound angiotensin
converting-enzyme (ACE). This classical
model has been incorporated in the
illustration in Figure 1. However this pathway
to angiotensin II generation is truly skeletal.
In the context of contemporary research it is
more constructive to view the RAS as
consisting of obligatory components
(angiotensinogen, angiotensin II and specific
receptors) linked by alternative, non-exclusive
components (renin, ACE and their functional
homologues [4, 5]). It is therefore more
accurate to describe the RAS as a major
“angiotensin-generating system”, rather than
the definitive enzymatic cascade of
angiotensin II generation. The classical
description of the RAS also undermines the
reality that angiotensin II formation is not
restricted to the circulation but is formed in
numerous tissues as diverse in function as the
brain [1, 6, 7], pituitary [6, 8], heart [9],
kidney [10], gonads [11, 12], and pancreas
(vide infra). It may even be formed
intracellularly [8, 10, 13]. The emphasis on
angiotensin II as the biologically relevant
product has also undergone extensive
revision, as what were once regarded
metabolic “fragments” of angiotensin II have
become products with specific actions
mediated by selective receptors [14]. For
example angiotensin III is involved in the
central regulation of blood pressure and
preferentially binds to the AT1b receptor [15,
16], angiotensin IV has vasodilatory,
antiproliferative and cognitive actions [17,
18] and angiotensin-(1-7) is a vasorelaxant
[19, 20, 21]. The final level of complexity is
added by the variety of angiotensin (AT)
receptors. Presently the major recognized AT
receptors includes the AT1 (subtypes a and b)
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and AT2 receptors for angiotensin II and
angiotensin III action [1, 2, 3, 9]. Although
the gene has yet to be identified, there is
strong evidence that angiotensin IV acts via
an AT4 receptor [22], and on the basis of the
heterogeneity of ligand binding, via a second
AT4b receptor subtype [23]. There is evidence
for an AT-(1-7) binding site for angiotensin-
(1-7) action, but a definitive identification of
this binding site has thus far eluded
researchers [19, 20, 21]. This array of
enzymatic paths leading to several
biologically active angiotensins, targeting
tissues with their respective receptors, is a
distant and vastly different system from the
classical RAS. Its complexity provides the
opportunity for functional diversity and for
multiple levels of control points. The
elucidation and understanding of these
angiotensin-generating systems has led to a
corresponding expansion of the domain for
angiotensin action, far beyond its modest
beginning as a vasoconstrictor hormone.
Figure 1. Diagram of the classical renin-angiotensin II
pathway with additional biologically active
angiotensins and their receptors.
Angiotensin-Generating Systems in the
Pancreas
Evidence for intrinsic angiotensin-generating
systems has been found in pancreatic tissues
and cell lines of the mouse, rat, dog and man
[24, 25, 26, 27, 28, 29]. The evidence has
been summarized in Table 1. The protein for
the obligatory component angiotensinogen
has been reported for the rat [24] and dog [25]
pancreas and its mRNA identified by reverse
transcriptase polymerase chain reaction (RT-
PCR). Immunocytochemistry has shown it to
be localized in the epithelium of pancreatic
ducts and in the vascular endothelium [24].
The islet cells do not show angiotensinogen
immunocytochemically, yet islet cell lines do
express angiotensinogen [30]. Thus a low or
intermittent expression of angiotensinogen in
islet cells in particular stimulatory
circumstances, such as hypoxia [31],
pancreatitis [32, 33] or other inflammatory
conditions, should not be overlooked. The
tissue content of angiotensinogen is low
compared to blood [25], indicating the
presence of highly localized angiotensin
generation in the vasculature and ducts, and
possibly the islets. Renin, (more precisely,
prorenin), has been identified in the human
pancreas [26]. While renin was localized by
immunocytochemistry to the vascular
endothelium and beta-cells, renin mRNA was
found in vascular fibroblasts and reticular
fibres of the islets. This cellular separation of
prorenin from its mRNA suggests that
prorenin may be used in the intracellular
generation of angiotensin II by endothelium
and beta-cells, in addition to any extracellular
role. There is partial support for an
intracellular angiotensin II system from the
findings of Leung et al [29], which localized
angiotensin II immunocytochemically to
endothelial cells and ductal epithelia.
However they found no angiotensin II in islet
cells, implying that the renin in beta-cells [24]
is not used to generate angiotensin II or more
likely, that angiotensin II is formed and
immediately secreted. This secreted
angiotensin II would then act in a paracrine
fashion on beta-cells via AT1 receptors and on
adjacent islet cells which, at least in the
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rodent, express higher densities of AT
receptors than beta-cells [34]. The direct
function of angiotensin II on islets cells may
well be the regulation of cell growth rather
than the regulation of hormone secretion [35,
36]. ACE is predictably found in the vascular
endothelium, preferentially in the islet
vasculature [37], as well as in islet cells [36].
One of the striking features of the research on
the angiotensin-generating systems in the
pancreas is the coincidence in the localization
of renin, angiotensinogen and angiotensin II.
Based on these current observations the
predominant pathway to angiotensin II
production in the pancreas strongly favours
the classical angiotensinogen-renin-ACE axis.
The failure to detect angiotensin I by
Chappell et al [25] seems to undermine this
view, until one considers that these authors
also failed to detect renin activity as well, in
contrast to later studies using renin-specific
techniques [24, 26].
Table 1. Summary of the presence or absence and the location in the pancreas of major components of the renin-
angiotensin system.
RAS component Absence/Presence Location Reference
Angiotensinogen Present Epithelium of ducts,
Vascular endothelium
[24, 25]





Present Vasculature, Pancreatic cell line [36, 37]
Angiotensin II Present Ductal epithelium,
Vascular endothelium
[29]
Angiotensin III Present ? [25]
Angiotensin IV ? ?
Angiotensin-(1-7) Present ? [25]
AT1 receptor AT1a, AT1b present Throughout pancreas [24, 26, 27, 28, 31, 34]
AT2 receptor Present Throughout pancreas [24, 27, 28, 34]
AT4 receptor ? ?
AT-(1-7) site ? ?
Receptors, which mediate angiotensin II
action, have a widespread distribution in the
pancreas [26, 27, 28, 31, 33, 34, 38, 39]. The
abundance of AT2 receptors appears to be
greater than AT1 receptors [27, 34],
nevertheless their distribution covers islets
cells, acinar cells, duct cells and vascular
tissue. Such a wide distribution is an
indication of the variety of roles in which
angiotensin II is likely involved in addition to
the already established regulation of
pancreatic blood [37] and ducal anion
secretion [40]. Further support for this view is
provided by the presence of both AT1a and
AT1b subtypes and the predominance of AT2
receptors [24, 26, 27, 28, 34], which are
known to mediate growth and differentiation
in direct opposition to AT1-mediated actions
[9, 41]. It is thus appropriate that the
pancreatic RAS be considered of importance
in conditions like pancreatitis, hypoxia and in
any inflammatory pancreatic event.
While there is an impressive amount still to
be uncovered about the “classical” pancreatic
RAS, the most deficient area is in the
investigation of alternate pathways to the
production of angiotensins [1, 2, 4, 5, 14, 15],
and in the expression of non-angiotensin II
AT receptors [3, 18, 20, 22]. Kallikreins
capable of generating angiotensin II
independently of renin are present in the
pancreas [5], thus implying the potential for
alternative angiotensin II generating
pathways. In addition, angiotensin III and
angiotensin-(1-7) have been identified, albeit
at lower concentrations than angiotensin II, in
the canine pancreas [25]. Their presence
implies the existence of aminopeptidases
capable of cleaving these peptides directly
from angiotensinogen or from angiotensin II.
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However, the peptidases or proteases
responsible for angiotensin II and
angiotensin-(1-7) production have not been
identified in the pancreas. It is interesting that
insulin has the ability to change the activity of
aminopeptidases capable of angiotensin
hydrolysis [42]. Hence there may be a
reciprocal role between insulin regulation of
local angiotensins production and the RAS
regulation of pancreatic activity. Angiotensin-
(1-7), having actions which oppose those of
angiotensin II [19, 20, 21], raises the
possibility of differential blood flow in the
pancreas due to a balance between
angiotensin II and angiotensin-(1-7). The
present limited data do not allow more than
speculation on this possibility. Finally, the
hexapeptide angiotensin IV has in recent
times attracted a great deal of attention
because of its vasodilatory, antihypertrophic
and cognitive-enhancing actions [3, 17, 18].
Furthermore, there is at least one AT4
receptor site selective for angiotensin IV that
has been partially characterized [22]. Based
on ligand-binding heterogeneity, there may be
a second AT4b site [23]. There is no
information on any aspect of angiotensin IV
physiology in the pancreas. The peptide has
not been identified or localized nor has its
function been tested. Similarly, AT4 receptors
have not been identified and localized in the
pancreas.
Future Directions
The current evidence for an intrinsic RAS in
the pancreas is persuasive and indicates that it
is of importance in normal exocrine and
endocrine functions, as well as in pathological
conditions. There is still uncertainty as to the
precise location of the components, their
relative abundance and which intracellular or
extracellular pathways are operative in the
generation of angiotensin II. However, the
least understood aspects are found in our
understanding of the “non-classical” RAS
which contains enzymes alternative to ACE
and renin, the production of biologically
active angiotensins in addition to angiotensin
II and the presence of receptors for these
additional angiotensin peptides. These areas
of research should lead to a fuller
understanding of the mechanisms which
operate in the normal pancreas and how their
derangement leads to pathological
manifestations, and vice versa.
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